DaVita Inc. (DVA) SEC Filings & Earnings Calls
EquiReason read 11 DaVita Inc. SEC filings in the last 12 months. Latest: 10-Q on 2026-08-04 — DaVita reported strong operating results with revenue growth, improved margins, and significantly higher free cash flow..
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 11.7B
- P/E TTM
- 15.1
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
4 Aug 202610-QDaVita reported strong operating results with revenue growth, improved margins, and significantly higher free cash flow.earningsopen
Figures in the filing · each found in the filing text
| Net income · H1-2026 | $618M | +22% y/y |
| Operating cash flow · H1-2026 | $811M | +61% y/y |
| Dialysis centers operated (U.S.) · U.S. · Q2-2026 | 2,671 | |
| Dialysis centers operated (International) · International · Q2-2026 | 595 | |
| U.S. IKC revenue · U.S. IKC · Q2-2026 | $162M | |
| International revenue · International · Q2-2026 | $386M |
Risks flagged
Concentration of profits from commercial payor plans
“The concentration of profits generated by higher-paying commercial payor plans for which there is continued downward pressure on average realized payment rates.” · word for word
Cybersecurity incident impact on collections
“Favorable changes in working capital, benefiting from favorable collections during the six months ended June 30, 2026 compared to the disruption in collections related to the cybersecurity incident.” · word for word
4 Aug 20268-K · 2.02DaVita Q2 2026: revenue $3.554B, operating income $579M (16.3% margin), EPS $4.02 vs $2.87 prior quarter; raised FY2026 adjusted operating income guidance to $2.15-2.25B and adjusted EPS to $14.10-15.20; free cash flow $256M; repurchased 2.earningsopen
Figures in the filing · each found in the filing text
| Consolidated revenues · Q2-2026 | $3.55B | |
| Operating income · Q2-2026 | $579M | |
| Diluted earnings per share · Q2-2026 | $4.02 | |
| Operating cash flow · Q2-2026 | $490M | |
| Free cash flow · Q2-2026 | $256M | |
| Revenue per treatment · U.S. dialysis · Q2-2026 | $415.87 | |
| Patient care costs per treatment · U.S. dialysis · Q2-2026 | $277.40 | |
| Total U.S. dialysis treatments · U.S. dialysis · Q2-2026 | 7,226,600 | |
| Outpatient dialysis centers · Q2-2026 | 3,266 | |
| International dialysis centers · International · Q2-2026 | 595 |
Guidance
FY2026 adjusted operating income $2.15-2.25B; adjusted diluted EPS $14.10-15.20; free cash flow $1.0-1.25B
DaVita raised FY2026 adjusted operating income and EPS guidance, reflecting confidence in margin expansion and steady volume growth.
Risks flagged
Cybersecurity incident in 2025 may still pose residual costs or reputational risk
“costs related to the cybersecurity incident experienced by the Company in 2025” · word for word
Changes in payor mix and government reimbursement rates could pressure revenue per treatment
“changes in payor mix and other normal fluctuations partially offset by seasonal impact of co-insurance and deductibles” · word for word
Increased competition and potential impact of innovative technologies or drugs on dialysis industry
“expectations regarding increased competition and marketplace changes, including those related to new or potential entrants in the dialysis and pre-dialysis marketplace and the potential impact of innovative technologies, drugs, or other treatments on the dialysis industry” · word for word
8 Jun 20268-K · 1.01, 2.03, 5.07DaVita entered a Ninth Amendment to its credit agreement, adding $500M in incremental term loans (Tranche B-2) to repay revolver borrowings and for general corporate purposes. No change in financial condition or performance implied.open
Risks flagged
Increased leverage from additional debt may raise financial risk.
“The Company has used or will use the proceeds of the Incremental Tranche B-2 Term Loans to repay a portion of its outstanding senior secured revolving loan facility and for general corporate purposes.”
5 May 20268-K · 2.02Consolidated revenues $3.42B; Operating income $482M (+10% y/y); Diluted EPS from continuing operations $2.87 (+44% y/y)earningsopen
Figures in the filing · each found in the filing text
| Consolidated revenues · Q1-2026 | $3.42B | |
| Operating income · Q1-2026 | $482M | +10% y/y |
| Diluted EPS from continuing operations · Q1-2026 | $2.87 | +44% y/y |
| Operating cash flow · Q1-2026 | $321M | +78% y/y |
| Free cash flow · Q1-2026 | $140M | |
| U.S. dialysis treatments per day · U.S. Dialysis · Q1-2026 | 91,650 | |
| Revenue per treatment · U.S. Dialysis · Q1-2026 | $417.59 | +4% y/y |
| Patient care costs per treatment · U.S. Dialysis · Q1-2026 | $280.11 | +3% y/y |
| Total patients · Q1-2026 | 296,300 | |
| Outpatient dialysis centers · Q1-2026 | 3,262 |
Risks flagged
Patient care costs per treatment increased 3.1% YoY, driven by compensation and insurance costs.
“Patient care costs: The change from prior year quarter was primarily driven by increased compensation expenses, insurance costs and medical supplies expense.”
5 May 202610-QTotal revenues $3.42B (+6% y/y); Net income attributable to DaVita Inc. $198M (+21% y/y); U.S. dialysis average patient service revenue per treatment $417.59 (+4% y/y)open
Figures in the filing · each found in the filing text
| Total revenues · Q1-2026 | $3.42B | +6% y/y |
| Net income attributable to DaVita Inc. · Q1-2026 | $198M | +21% y/y |
| U.S. dialysis average patient service revenue per treatment · U.S. dialysis · Q1-2026 | $417.59 | +4% y/y |
| U.S. dialysis patient care costs per treatment · U.S. dialysis · Q1-2026 | $280.11 | +3% y/y |
| U.S. dialysis treatments · U.S. dialysis · Q1-2026 | 7,029,525 | -0% y/y |
| Operating cash flow · Q1-2026 | $321M | +78% y/y |
| Free cash flow · Q1-2026 | $140M | +411% y/y |
| International dialysis centers · Other - Ancillary services · 2026-03-31 | 596 | +16% y/y |
Risks flagged
Government Investigations
“The Company is subject to various governmental investigations, including from the U.S. Attorney's Office, California Department of Insurance, and Federal Trade Commission.”
Labor Cost Inflation
“U.S. dialysis patient care costs per treatment increased 3.1% year-over-year, primarily due to increased compensation expenses and wage rates.” · word for word
Regulatory and Reimbursement Risk
“Changes in government payment rates under Medicare, Medicaid, or other programs could materially impact revenues.”
High Leverage
“Long-term debt of $10.5 billion as of March 31, 2026, with significant interest expense of $145 million in Q1 2026.”
22 Apr 2026DEF 14ADaVita filed its definitive proxy statement (DEF 14A) for the 2026 Annual Meeting of Stockholders.open
Figures in the filing · each found in the filing text
| Operating income · FY2025 | $2.04B | |
| Adjusted operating income · FY2025 | $2.09B | |
| Earnings per share from continuing operations · FY2025 | $9.51 | |
| Adjusted earnings per share from continuing operations · FY2025 | $10.78 | |
| Operating cash flows · FY2025 | $1.89B | |
| Free cash flows · FY2025 | $1.02B | |
| Consolidated patient census growth · FY2025 | 5.0% | |
| U.S. dialysis revenue growth · U.S. dialysis · FY2025 | 4.0% | |
| International revenue growth · International · FY2025 | 38.0% | |
| Shares repurchased · FY2025 | 12,700,000 |
Guidance
Long-term growth targets of 3-7% adjusted operating income and 8-14% adjusted diluted EPS
Management reaffirms long-term growth targets and highlights 2025 performance in-line with these targets.
Risks flagged
Cybersecurity incident risk
“our response to an April cybersecurity incident stands out. Through the resilience of our frontline caregivers and the expertise of our technology teams, we activated contingency plans and provided continued care across more than 3,000 dialysis centers worldwide.” · word for word
Regulatory and compliance risk
“The Compliance and Quality Committee oversees non-financial compliance risk, including that associated with healthcare and anti-corruption-related requirements.” · word for word
Concentration of ownership risk
“Warren E. Buffett Berkshire Hathaway Inc. ... 30,100,585 45.5 %”
11 Feb 202610-KU.S. dialysis patients 200,500; International dialysis centers 585; International dialysis patients 94,500open
Figures in the filing · each found in the filing text
| U.S. dialysis patients · U.S. dialysis · 2025-12-31 | 200,500 | |
| International dialysis centers · International · 2025-12-31 | 585 | |
| International dialysis patients · International · 2025-12-31 | 94,500 | |
| IKC risk-based patients · U.S. integrated kidney care · 2025-12-31 | 66,000 | |
| U.S. dialysis outpatient centers · U.S. dialysis · 2025-12-31 | 2,657 | |
| U.S. dialysis revenue as % of consolidated revenue · U.S. dialysis · FY2025 | 86.0% | |
| Medicare/Medicare Advantage revenue % · U.S. dialysis · FY2025 | 57.0% |
Risks flagged
Medicare Reimbursement Risk
“Uncertainty about future payment rates remains a material risk to our business, as well as the potential implementation of or changes in coverage determinations or other rules or regulations by CMS or Medicare Administrative Contractors that may impact reimbursement.” · word for word
Regulatory Compliance Risk (Anti-Kickback/Stark/FCA)
“If any of our current or previous business transactions or arrangements... were found to violate the federal Anti-Kickback Statute, we, among other things, could face such penalties and sanctions, and depending on the nature of the violation, these penalties and sanctions could be material.” · word for word
Commercial Payor Mix Shift
“When Medicare becomes the primary payor, the payment rates we receive for that patient shift from the commercial insurance plan rates to Medicare payment rates, which are on average significantly lower than commercial insurance rates.” · word for word
GLP-1 Drug Impact on Patient Volume
“certain of these factors, in particular mortality rates for dialysis or CKD patients, have been impacted by global health conditions, including severe flu seasons and the ongoing incidence of other infectious diseases such as COVID-19.” · word for word
2 Feb 20268-K · 2.02Consolidated revenues $3.62B; Operating income $561M; Adjusted operating income $586Mearningsopen
Figures in the filing · each found in the filing text
| Consolidated revenues · Q4-2025 | $3.62B | |
| Operating income · Q4-2025 | $561M | |
| Adjusted operating income · Q4-2025 | $586M | |
| Diluted EPS from continuing operations · Q4-2025 | $2.94 | |
| Adjusted diluted EPS from continuing operations · Q4-2025 | $3.40 | |
| Operating cash flow · Q4-2025 | $541M | |
| Free cash flow · Q4-2025 | $309M | |
| Total U.S. dialysis treatments · U.S. dialysis · Q4-2025 | 7,264,520 | |
| Revenue per treatment · U.S. dialysis · Q4-2025 | $422.60 | |
| Patient care costs per treatment · U.S. dialysis · Q4-2025 | $279.60 |
Risks flagged
Patient care costs per treatment increased QoQ due to health benefit and medical supply costs.
“Patient care costs per treatment $279.60 vs $273.54 in Q3 2025; driven by increased health benefit expense and medical supply costs.”
Mozarc investment impairment and restructuring charges of $20.5M.
“Incurred impairment and restructuring charges of $20.5 million as part of equity investment losses related to Mozarc.” · word for word
25 Nov 20258-K · 1.01, 2.03Entered a material definitive agreement (acquisition, partnership, or major contract); took on a material direct financial obligation, increasing leverageopen
Risks flagged
Debt covenant risk; amendment may indicate changes in financial terms.
“Eighth Amendment to Credit Agreement; specific terms not disclosed in excerpt.”
29 Oct 20258-K · 2.02Consolidated revenues $3.42B; Operating income $506M; Adjusted diluted EPS $2.51; Guidance: Full-year guidance on trackearningsopen
Figures in the filing · each found in the filing text
| Consolidated revenues · Q3-2025 | $3.42B | |
| Operating income · Q3-2025 | $506M | |
| Adjusted diluted EPS · Q3-2025 | $2.51 | |
| Operating cash flow · Q3-2025 | $842M | +4% y/y |
| Free cash flow · Q3-2025 | $604M | +9% y/y |
| Revenue per treatment · U.S. dialysis · Q3-2025 | $410.59 | |
| Patient care costs per treatment · U.S. dialysis · Q3-2025 | $273.54 | |
| Total U.S. dialysis treatments · U.S. dialysis · Q3-2025 | 7,242,725 |
Guidance
Full-year guidance on track
Q3 performance in line with expectations; full-year guidance reaffirmed; management tone positive
Risks flagged
Cybersecurity incident costs; $11.7M in Q3, $25.2M YTD
“Cybersecurity incident-related charges of $11.7 million in Q3 2025; $25.2 million YTD”
Mozarc investment losses; $51.3M including $25.9M impairment/restructuring
“Equity investment losses related to Mozarc of $51.3 million which included impairment and restructuring charges of $25.9 million”
29 Oct 202510-QDaVita reported Q3 2025 results with international growth offset by lower operating cash flow, increased share repurchases, and equity investment losses.earningsopen
Figures in the filing · each found in the filing text
| Total revenue · ancillary_services · Q3-2025 | $455M | |
| Net income · 9M-2025 | $748M | -17% y/y |
| Free cash flow · 9M-2025 | $716M | -19% y/y |
| Operating cash flow · 9M-2025 | $1.35B | -9% y/y |
| Centers dialysis · U.S. · 2025-09-30 | 2,662 | |
| Centers dialysis international · International · 2025-09-30 | 585 | +29% y/y |
| Operating income · ancillary_services · Q3-2025 | $1M |
Risks flagged
Commercial payor mix dependency
“the concentration of profits generated by higher-paying commercial payor plans for which there is continued downward pressure on average realized payment rates; a reduction in the number or percentage of our patients under commercial plans” · word for word
Labor cost and shortage
“the current challenging and highly competitive labor market conditions, including due to the ongoing nationwide shortage of skilled clinical personnel” · word for word
Cybersecurity incident impact
“the cybersecurity incident experienced by the Company in 2025” · word for word
Equity investment losses
“equity investment losses at Mozarc Medical Holding LLC (Mozarc) which included impairment and restructuring charges of $25.9 million” · word for word
Government contract awards
federal awards · contract value, often multi-year| Date | Agency | Value | What for |
|---|---|---|---|
| 2025-12-17 | Department of Veterans Affairs | $121M | EXPRESS REPORT: FY 26 NOVEMBER NDSC EXPRESS REPORT |
| 2025-11-13 | Department of Veterans Affairs | $27M | EXPRESS REPORT: FY 26 OCTOBER NDSC EXPRESS REPORT |
DaVita Inc. — questions
- What did DaVita Inc. file recently?
- 11 SEC filings in the last 12 months. Latest: 10-Q on 2026-08-04 — DaVita reported strong operating results with revenue growth, improved margins, and significantly higher free cash flow.
Every figure on this page comes from DaVita Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.